Skip to main content

Advertisement

Table 1 Health care resource use by line of therapy and regimen in Italy, Spain, Germany, and Australia

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

  Italy Spain Germany Australia
(N = 174) (N = 202) (N = 139) (N = 208)
Characteristic N a Inpatient stayb Outpatient visit N a Inpatient stay Outpatient visit N a Inpatient stay Outpatient visit N a Inpatient stay Outpatient visit
First-line therapyc 149 36 (24) 143 (96) 130 55 (42) 121 (93) 81 61 (75) 56 (69) 184 83 (45) 177 (96)
 Platinum-based comb. 119 28 (24) 116 (98) 107 49 (46) 98 (92) 73 54 (74) 52 (71) 156 75 (48) 150 (96)
 Non-platinum comb. 0 0 0 3 1 (33) 3 (100) 0 0 0 0 0 0
 Single agent 15 2 (13) 13 (87) 9 1 (11) 9 (100) 4 3 (75) 1 (25) 15 4 (27) 14 (93)
 EGFR/ALK TKI 15 6 (40) 14 (93) 11 4 (36) 11 (100) 4 4 (100) 3 (75) 13 4 (31) 13 (100)
Second-line therapyc 89 20 (22) 88 (99) 68 d 30 (44) 64 (94) 37 27 (73) 32 (87) 118 55 (47) 114 (97)
 Platinum-based comb. 12 3 (25) 12 (100) 14 7 (50) 14 (100) 11 9 (82) 8 (73) 21 7 (33) 21 (100)
 Non-platinum comb. 0 0 0 6 4 (67) 6 (100) 2 1 (50) 1 (50) 1 0 1 (100)
 Single agent 45 12 (27) 44 (98) 34 9 (27) 33 (97) 17 11 (65) 16 (94) 71 34 (48) 69 (97)
 EGFR/ALK TKI 32 5 (16) 32 (100) 12 9 (75) 9 (75) 7 6 (86) 7 (100) 25 14 (56) 23 (92)
  1. Data are n (%) unless otherwise noted
  2. aN represents patients with available HCRU data
  3. bAn inpatient stay was defined as one or more nights in a hospital or hospice
  4. cThe systemic therapy categories were defined as follows:
  5. • Platinum-based combination: regimen with two or more anticancer therapies including carboplatin or cisplatin
  6. • Non-platinum combination: regimen with two or more anticancer therapies not including carboplatin or cisplatin (can contain bevacizumab in combination with other non-platinum drug)
  7. • Single agent: regimen of one anticancer drug that was not an EGFR or ALK tyrosine kinase inhibitor (TKI)
  8. • EGFR/ALK TKI: monotherapy with anti-EGFR (erlotinib, gefitinib, afatinib) or anti-ALK agent (crizotinib, ceritinib)
  9. • Other NSCLC anticancer agent: any other agent not included in the prior categories
  10. dIn Spain during second-line therapy, “Other” NSCLC agents were administered to 2 patients, one of whom had an inpatient stay and both of whom had outpatient visits
  11. ALK anaplastic lymphoma kinase, comb. combination, EGFR epidermal growth factor receptor, NSCLC non-small cell lung cancer, TKI tyrosine kinase inhibitor